Mallinckrodt plc (MNKKQ) Stock

About Mallinckrodt plc

Headquartered in Dublin, Ireland, Mallinckrodt plc is engaged in the global development, manufacturing, commercialization, and distribution of specialized pharmaceutical products and therapeutic solutions. The company operates through two primary divisions: Specialty Brands and Specialty Generics. Its Specialty Brands division focuses on proprietary pharmaceutical products addressing autoimmune and rare diseases across multiple therapeutic areas, including neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. This segment also encompasses immunotherapies, neonatal respiratory critical care treatments, analgesics, cultured skin substitutes, and gastrointestinal medications. Among its flagship products are Acthar Gel, a repository corticotropin injection prescribed for various conditions such as rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, and severe acute and chronic allergic and inflammatory diseases. Other notable offerings include INOmax, a vasodilator designed to improve oxygenation and reduce the necessity for extracorporeal membrane oxygenation; the Therakos photopheresis immunotherapy platform; Amitiza for constipation; and StrataGraft, indicated for adults with deep partial-thickness burns. Additionally, Mallinckrodt is advancing pipeline candidates like Terlipressin for hepatorenal syndrome and SLN 501, an investigational ribonucleic acid silencing therapy. The Specialty Generics division supplies specialized generic drugs and active pharmaceutical ingredients. The company's branded products are marketed to a broad spectrum of healthcare professionals and entities, including physicians, respiratory therapists, pharmacists, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc also maintains a collaboration with Silence Therapeutics plc for the development and commercialization of ribonucleic acid interference drug targets. Established in 1867, Mallinckrodt plc and its affiliates initiated voluntary reorganization proceedings under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on October 12, 2020.

the stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.02 and $0.02, and currently trades at its 52-week high.

On profitability, Mallinckrodt plc generates a return on equity (ROE) of -23.68%, return on capital employed of -11.70%, an operating margin of -31.94%, a net profit margin of -34.17%.

Official website: www.mallinckrodt.com